Nephrology

Back to articles

Lower uric acid levels may be better in chronic kidney disease

January 4, 2016

Advising on this article:
Edward Foote

Email this article

KEY POINT

Use of febuxostat (Uloric—Takeda) 40 mg once daily for 6 months in patients with asymptomatic hyperuricemia and stage 3 or 4 chronic kidney disease (CKD) slowed the decline in estimated glomerular filtration rate (eGFR) compared with placebo, according to results of a small, single-center study published in the American Journal of Kidney Diseases.

SOURCES

Sircar D et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;945–50.

Levy G et al. Is it time to start treating asymptomatic hyperuricemia [editorial]? Am J Kidney Dis. 2015;933–5.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter. 2013 (Suppl);3:1–150.

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.